QUANTITATING THE IMPACT OF CLINICAL AND BASIC SCIENCE RESEARCH POSTER #2469

M. O. GORDON, C. SARLI, E. K. DUBINSKY, E. LONG, C. LA RUE, M. A. KASS, AND THE OCULAR HYPERTENSION TREATMENT STUDY (OHTS) GROUP

OPHTHALMOLOGY AND VISUAL SCIENCES, BECKER MEDICAL LIBRARY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS, MISSOURI

SUPPORTSupport: NIH Grants EY 09307, EY 09341, EY015498, National Center on Minority Health and Health Disparities, UL1 RR024992 of the National Center for Research Resources, Horncrest Foundation, Merck Research Laboratories, and Pfizer, Inc. This work was also supported by awards to the Department of Ophthalmology and Visual Sciences, Washington University from a Research to Prevent Blindness, Inc. Unrestricted grant, and the NIH Vision Core Grant P30 EY 02687

OHTS demonstrates that citation counts alone are inadequate to assess research impact. Impact should also include research output, knowledge transfer, and clinical implementation. To help document research impact, an interactive website was developed: Assessing the Impact of Research. (http://becker.wustl.edu/impact/assessment/index.html).

Documentation of research impact will be a useful tool for progress reports, grant applications, and promotion dossiers.

RESEARCH OUTPUT KNOWLEDGE TRANSFER CLINICAL IMPLEMENTATION

What was CREATED by a research study? How was the research output DISSEMINATED?

How was the research output USED? How was AWARENESS of research output demonstrated?

How was TRANSLATION of research output into clinical applications demonstrated?

DOCUMENTED EVIDENCE OF RESEARCH OUTPUT

•Publications 29 peer-reviewed manuscripts published to date.

•Website of Research Study(https://vrcc.wustl.edu/)

•Media Releases Dryden, Jim. Model can predict risk of glaucoma in patients with elevated eye pressure. Washington University Medical Public Affairs News Release. November 14, 2006.

•Conference Presentations OHTS presentations (abstracts and papers) at national and international conferences:

DOCUMENTED EVIDENCE OF KNOWLEDGE TRANSFER

•Cited References The OHTS outcome and prediction papers were in the top 10% of cited papers published in 2002 from 25 medical and biomedical specialties (Source: Essential Science Indicators).

•Research Studies/Ancillary Corneal Endothelial Cell Density Genetics Ancillary Study R-01 Short Wavelength Automated Perimetry

R-01 Confocal Scanning Laser Ophthalmoscopy R-01 Pachymetry Ancillary Study R-21 European Glaucoma Prevention Study (EGPS) /OHTS Collaborative Analysis R-21 EGPS/OHTS Confocal Scanning Laser Ophthalmoscopy Collaboration

•Meta Analyses Maier PC, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. British Medical Journal 2005;331:134-40.

•Curriculum GuidelinesThe International Council on Ophthalmology (ICO): Principles and Guidelines for the Curriculum for Education of the Ophthalmic Specialist and an appendix, Glaucoma: Ocular Hypertension Treatment Study (OHTS), 2006.

DOCUMENTED EVIDENCE OF CLINICAL IMPLEMENTATION

•Clinical/Practice Guidelines American Academy of Ophthalmology (AAO). Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern™ Guideline, 2005.

•Measurement Instruments Glaucoma Five Year Estimator Risk Calculator (STAR II), 2007. The Glaucoma Five Year Risk Estimator is based on

results from the OHTS and the EGPS.

•Coding Establishment of CPT III code for pachymetry in 2002. Establishment of CPT I code for pachymetry in 2004.

•Continuing Education Materials Review of Optometry. 13th Annual Glaucoma Report: Calculate the Risk Factors For Glaucoma, 2007.

•Quality Measure Guidelines The National Committee for Quality Assurance (NCQA), Health Plan Employer Data and Information Set (HEDIS). --HEDIS Glaucoma Screening in Older Adults (GSO) Measure (first year optional Senior measure), 2005. --HEDIS Glaucoma Screening in Older Adults (GSO) Measure (required Senior measure), 2006-2009.

012345678

1994 1996 1998 2000 2002 2004 2006

PURPOSE: To quantitate the impact of biomedical research on generation of new knowledge and change in clinical practice. Governments world-wide are demanding quantifiable outcome measures of research impact .

METHODS FOR DOCUMENTING IMPACT

References:Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR,

Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 2002; 120:701-713.

Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141:997-1008.

The Ocular Hypertension Treatment Study (OHTS) Group and the European Glaucoma Prevention Study (EGPS) Group. A validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19.

CONCLUSION